Peerview Oncology & Hematology Cme/cne/cpe Audio Podcast

Go online to PeerView.com/UDV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While recurrent or advanced endometrial cancer (EC) has traditionally been associated with a poor prognosis, the use of immune checkpoint inhibition (ICI) in both monotherapy and combination approaches has led to improved outcomes. These gains have been well established in the second-line setting with multiple regulatory approvals, and ICIs have recently been shown to have an impact in the frontline setting, further altering the standard of care. In this activity, based on a recent live symposium, a panel of experts provides participants with foundational knowledge on the mechanistic rationale and up-to-date evidence supporting the use of ICIs in patients with advanced EC. Through discussion of real-life patient cases, the faculty provides practical guidance on incorporating approved and emerging approaches into clinical practice. Featured topics include biomarker testing, clini

Go online to PeerView.com/DGX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovation in renal cell carcinoma (RCC) has brought new opportunities to improve patient outcomes through personalized medicine. With multiple FDA approvals and promising agents being explored in a variety of settings, multitargeted TKIs and immune checkpoint inhibitors have earned their place in cancer care plans either as guideline-recommended therapy or through clinical trial enrollment. In this activity, which was based on a recent live event, a panel of expert oncologists combines a concise overview of essential research on approved and emerging RCC treatments with discussion of real-life patient cases to provide guidance on integrating validated strategies into everyday patient care. Learn how patient-, disease-, and treatment-specific factors affect therapeutic selection and sequencing—including when to consider adjuvant therapy, which patients may benefit from immunothe

Go online to PeerView.com/GUW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent symposium held during the 2023 ASCO Annual Meeting, leading experts guide you through the winning era of immunotherapy in melanoma. Through a series of linked lectures and debates, the panel discusses the integration of modern immunotherapy combination and sequential options in advanced disease and considers options for patients progressing on prior immunotherapy. They also examine new developments with immunotherapy in the adjuvant and neoadjuvant settings. Upon completion of this activity, participants should be better able to: Discuss current guidelines, efficacy, and safety data surrounding the use of immunotherapy in melanoma as neoadjuvant or adjuvant therapy in resectable disease or as part of novel combinatorial or sequential approaches for unresectable disease; Craft team-based treatment plans that include immunotherapy for resectable

Go online to PeerView.com/KYR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how the experts “defy the odds” every day by exposing patients with chronic lymphocytic leukemia (CLL) to the clinical benefits of innovative therapy! Novel therapeutics based on BTK and BCL2 inhibitor platforms have radically transformed the management of CLL and allowed for a greater range of treatment options in a range of CLL settings. This MasterClass & Case Forum activity, adapted from a recent live event and developed in collaboration with the CLL Society, offers learners expert guidance on how to select and sequence agents over several lines of therapy while proactively integrating newer BTKi strategies, targeted combination platforms, and cellular immunotherapy into safe, personalized treatment plans. Throughout, learn about offerings from the CLL Society that will help you engage with patients and offer them the resources they need to contribute to care decis

Go online to PeerView.com/WFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Important advances have occurred in the treatment of small cell lung cancer (SCLC) in recent years, and more exciting progress in the form of improved understanding of the disease biology, subtypes, and novel therapies is on the horizon. This educational activity, based on a recent live symposium produced in collaboration with LUNGevity Foundation, offers useful guidance for navigating the evidence supporting the use of current and emerging therapies in SCLC and translating the latest science to everyday clinical practice. Upon completion of this activity, participants should be better able to: Discuss the rationale, current or emerging clinical roles, and evidence supporting the use of the latest therapies for SCLC; Integrate the current standard-of-care therapies into individualized treatment plans of eligible patients with SCLC based on the latest evidence, guideline recommen

Go online to PeerView.com/JQE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have transformed the frontline management of recurrent/metastatic head and neck cancer (HNC)—but how can oncology professionals build on that foundation to expand the therapeutic applications of immunotherapy in HNC? This “MasterClass & Case Forum” activity, taken from a recent live event, features a panel of leading HNC experts sharing case-based insights on clinical decision-making with immunotherapy in recurrent/metastatic disease and beyond. Developed in collaboration with the Head and Neck Cancer Alliance (HNCA), each case-centric session also features the latest evidence on established and emerging immune-based treatments, combinational and sequential approaches, and the potential of checkpoint blockade in resectable and locally advanced disease. Upon completion of this activity, participants should be better able to: Cite the latest clinic

Go online to PeerView.com/NXP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Emerging evidence supporting modern targeted strategies for the management of biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA) has led to the development of several agents to personalize therapy based on molecular findings. In this activity, our expert faculty will provide updates on evolving evidence-based practice standards and discuss how to effectively integrate the latest treatment advances into practice. You will learn to identify appropriate baseline diagnostic testing to inform the selection of targeted therapy for your patients with gastrointestinal cancers. Our experts will also introduce the latest evidence supporting relevant, novel strategies and explain when to initiate these agents in comparison with conventional treatment. Upon completion of this activity, participants should be better able to: Recognize current evidence supporting molecular

Go online to PeerView.com/TAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel antibodies, tyrosine kinase inhibitors, cellular therapy, and modern asparaginases, such as pegylated Escherichia coli and Erwinia chrysanthemi compounds have vastly improved treatment plans for pediatric and adolescent and young adult (AYA) populations with acute lymphoblastic leukemia (ALL). The approval of newer Erwinia formulations has expanded the therapeutic foundation on which clinicians can build effective strategies to address challenges such as asparaginase discontinuation due to hypersensitivity or silent inactivation. This "Clinical Consults" activity focuses on clinical decision-making related to the use of asparaginase compounds as part of pediatric and AYA ALL therapy. Watch experts provide guidance on the modern use of asparaginase therapy and share tactics for addressing real-world barriers to effective care, including hypersensitivity, silent inactivation

Go online to PeerView.com/VRD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the therapeutic landscape for gynecologic cancers (ovarian, endometrial, and cervical) rapidly evolves, how can oncology nurses effectively support patients and integrate the growing clinical evidence for approved and emerging strategies? Nurses can rise to the challenge with this PeerView Live MasterClass & Nursing Practice Forum, based on a recent live event developed in collaboration with the National Ovarian Cancer Coalition. An expert panel showcases what nursing professionals should know about diagnostic testing, PARP inhibitors, immunotherapy options, and managing potential adverse events. Through the lens of patient case scenarios, they will also share personal reflections on supporting patients throughout their treatment process. Upon completion of this activity, participants should be better able to: Review current efficacy and safety evidence of immunotherapy a

Go online to PeerView.com/RFJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent developments targeting the RAS/MAPK signaling pathway have led to the first approved MEK inhibitor for the treatment of pediatric patients with symptomatic, inoperable PNs. To help lay the foundation of personalized NF1 care, this activity—based on a live event at the recent ASPHO meeting—features expert panelists sharing real-world cases to illustrate the collaborative management of NF1 tumors with highly efficacious targeted agents. The case-based conversations cover the diagnostic-treatment arc of NF1-PNs, culminating with tips and tactics arising from the clinical experience with MEK inhibitors—and going beyond to include insights on targeted strategies in other NF1 tumor settings. Watch now to start building your personalized management on a bedrock of solid science! Upon completion of this activity, participants should be better able to: Summarize current evidence a

Go online to PeerView.com/NDY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are prepared to integrate cutting-edge antibody and CAR-T options for the care of patients with multiple myeloma (MM). In this PeerView Pharmacy MasterClass and Case Forum activity, an expert panel will offer guidance on how pharmacists can tackle the real-world challenges of MM management by facilitating care with CD38 and BCMA-directed antibodies, as well as CAR-T therapy, in a range of different treatment settings. Our experts will provide insights into how pharmacists can help modernize MM treatment protocols by ensuring appropriate care coordination and addressing safety, dosing, and therapy delivery considerations associated with CD38 and BCMA-directed treatment. Participate in this CPE video activity to see if you are prepared to lead the way to better outcomes for MM! Upon completion of this activity, participants should be better able to: Describe the me

Go online to PeerView.com/UNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this discussion-based activity, two experts on ovarian cancer discuss the role of PARP inhibitors in treating advanced ovarian cancer. Upon completion of this activity, participants should be better able to: Adapt workflows to ensure that patients with ovarian cancer are receiving timely and appropriate genetic testing for BRCA, HRD, and other mutations that can help determine the role of PARP inhibitor therapy; Cite current efficacy and safety evidence on PARP inhibitors in different populations of patients with ovarian cancer; Utilize PARP inhibitors in the appropriate management of patients with ovarian cancer, including within the context of clinical trials, in accordance with current clinical evidence, guideline recommendations, mutation status, and patient needs and preferences; and Employ collaborative strategies to recognize and manage adverse events related to PARP i

Go online to PeerView.com/AZG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you updated on the leading advances in CLL care and the role nurses play in ensuring the best outcomes for patients? Find out in this PeerView Nurse MasterClass, where a panel of leading CLL hematology-oncology nurse experts present state-of-the-art evidence supporting the use of highly efficacious targeted strategies in CLL, including covalent and non-covalent BTKi as well as BCL2i. Our experts will also present a rich collection of case examples from nursing practice designed to explore how nurses can be the cornerstone of the management team. This event recorded at the annual ONS Congress was developed in collaboration with the CLL Society and will also feature a patient video testimonial on the nurse–patient relationship and the key role of nurses as patient educators during the therapeutic journey. Get updated on the advances in CLL care and earn NCPD/ILNA credit today!

Go online to PeerView.com/SJV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Can you bet on BCMA for your patients with multiple myeloma (MM)? Based on their demonstrated ability to evade resistance to prior agents and induce deep and durable responses, BCMA CAR-T constructs and bispecific antibodies have emerged as core management options for patients with MM progressing on their therapeutic journey. In collaboration with the HealthTree Foundation for Multiple Myeloma, this expert oncology nurse–led activity uses case-based teaching examples to illustrate practical strategies for the delivery of care with BCMA therapeutics while highlighting strategies for patient education and safety management. Each presentation features resources and tools from the HealthTree Foundation for Multiple Myeloma designed to overcome some of the challenges patients face, increase awareness of BCMA-directed options, and foster collaboration between professionals and patient

Go online to PeerView.com/VTJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape for bladder cancer has rapidly evolved. The largely chemotherapy-based approaches of the past are giving way to the use of immune checkpoint inhibitors, targeted agents, and antibody–drug conjugates in advanced disease, as well as bladder-sparing and perioperative approaches in early-stage disease settings. How can oncology nurses synthesize the diverse body of clinical evidence on approved and emerging strategies into the realities of real-world cancer care to successfully address the therapeutic and educational needs of patients across the disease continuum? To help nurses rise to the challenge of modern bladder cancer management, this PeerView activity, based on a recent live event and developed in collaboration with the Bladder Cancer Advocacy Network, features an interprofessional expert panel that provides overview of the rationale and clinical ev

Go online to PeerView.com/CFM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a live MasterClass and Nursing Practice Forum, leading experts present concise learning modules combined with workshop-style demonstrations and case-based discussions to provide a practical framework for oncology nurses to facilitate optimal clinical integration of immunotherapies in advanced/metastatic and early-stage NSCLC, offering strategies to educate patients about this therapeutic class, mitigate acute and chronic immune-related adverse events (irAEs), and support patients through treatment and survivorship to help them achieve the best possible quality of life and outcomes. Upon completion of this activity, participants should be better able to: Describe the mechanisms of action, safety and efficacy, and current and emerging roles of immune checkpoint inhibitors (ICIs) and combinations in advanced- and early-stage NSCLC; Collaborate with the int

Go online to PeerView.com/SQN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immune checkpoint inhibitors have started to radically transform the perioperative treatment of resectable stage I-III NSCLC, with the goals of reducing the risk of recurrence and improving cure rates in these settings. Several important phase 3 clinical trials evaluating neoadjuvant and/or adjuvant immunotherapies have already yielded impressive data, leading to regulatory approvals and new standards of care, and additional studies have recently been reported to be positive, adding to the evidence base but also increasing complexity. What do these advances mean for thoracic surgeons, medical oncologists, and other multidisciplinary specialists, and what changes in practice are needed? What challenges and unanswered questions remain? This PeerView educational activity, based on a recent live symposium, brings together top experts to evaluate the new practice-changing resear

Go online to PeerView.com/PUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With adjuvant EGFR-targeted therapy now a new standard of care in resected stage I-III EGFR-mutated non-small cell lung cancer (NSCLC), what are the implications and considerations for the multidisciplinary, multimodal management of these patients? A panel of specialists in thoracic surgery and medical oncology consider this question as they discuss the importance of biomarker testing in early-stage lung cancer, the latest clinical evidence supporting the use of adjuvant EGFR-targeted therapy, and its potential expansion into the neoadjuvant setting, as well as other targeted therapies showing promise in perioperative settings. In addition, the panel demonstrates strategies for achieving better partnerships among thoracic surgeons, oncologists, pathologists, and other key specialists to facilitate predictive testing, clinical decision-making, and the optimal incorporation of EGF

Go online to PeerView.com/GFT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Oncology nurse professionals play a particularly important role in providing high-quality and increasingly personalized care to patients with acute myeloid leukemia (AML)—but how current are you with the “real-world” practice of nursing care in AML? Find out in this activity, featuring an oncology nurse’s expert overview of nursing principles that can be used to modernize care and optimize the use of innovative targeted therapies (such as FLT3, IDH1/2, and BCL-2 inhibitors) across the treatment continuum. Upon completion of this activity, participants should be better able to: Recognize clinical symptoms, patient-related factors, and molecular/genetic features that influence AML treatment decisions and prognosis; Summarize efficacy and safety evidence related to novel targeted and epigenetic options for the management of newly diagnosed AML, postremission disease, and the relaps

Go online to PeerView.com/NRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. HER2-low breast cancer, currently defined as HER2 IHC 1+ or 2+/ISH-, accounts for approximately 50% of all breast cancers. While older HER2-targeted therapies did not show efficacy in HER2-low breast cancers, novel antibody–drug conjugates (ADCs) have demonstrated remarkable activity in this setting. Because of these advances and the FDA approval of the first HER2-targeting ADC for HER2-low breast cancer, there is an urgent need to rethink the approaches to HER2 testing so that patients with HER2-low breast cancer could be identified and get a chance to benefit from the new therapeutic approach. The understanding, definitions, and testing for HER2-low status continue to evolve, and many practical challenges and unanswered questions remain. This PeerView educational activity, based on a recent live symposium, explores the most cutting-edge information on HER2-low breast cancer, p